Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs.

Autor:	Tsui JI; Department of Medicine, University of Washington School of Medicine, Division of General Internal Medicine University of Washington, Seattle, WA, United States., Gojic AJ; Department of Medicine, University of Washington School of Medicine, Division of General Internal Medicine University of Washington, Seattle, WA, United States., Pierce KA; Kelley-Ross Pharmacy Group, Seattle, WA, United States., Tung EL; Kelley-Ross Pharmacy Group, Seattle, WA, United States.; Department of Pharmacy, University of Washington, Seattle, WA, United States., Connolly NC; Department of Medicine, University of Washington School of Medicine, Division of General Internal Medicine University of Washington, Seattle, WA, United States., Radick AC; Department of Medicine, University of Washington School of Medicine, Division of General Internal Medicine University of Washington, Seattle, WA, United States., Hunt RR; Des Moines University College of Osteopathic Medicine, Des Moines, IA, United States., Sandvold R; Hepatitis Education Project, Seattle, WA, United States., Taber K; Hepatitis Education Project, Seattle, WA, United States., Ninburg M; Hepatitis Education Project, Seattle, WA, United States., Kubiniec RH; Evergreen Treatment Services, Seattle, WA, United States., Scott JD; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle WA, United States., Hansen RN; Kelley-Ross Pharmacy Group, Seattle, WA, United States.; Department of Pharmacy, University of Washington, Seattle, WA, United States.; Department of Health Systems and Population Health, University of Washington, Seattle, WA, United States., Stekler JD; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle WA, United States., Austin EJ; Department of Health Systems and Population Health, University of Washington, Seattle, WA, United States., Williams EC; Department of Health Systems and Population Health, University of Washington, Seattle, WA, United States.; Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research & Development, VA Puget Sound, Seattle WA, United States., Glick SN; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle WA, United States.; HIV/STI/HCV Program, Public Health - Seattle & King County, Seattle WA, United States.
Jazyk:	angličtina
Zdroj:	Drug and alcohol dependence reports [Drug Alcohol Depend Rep] 2023 Dec 23; Vol. 10, pp. 100213. Date of Electronic Publication: 2023 Dec 23 (Print Publication: 2024).
DOI:	10.1016/j.dadr.2023.100213
Abstrakt:	Background: People who inject drugs (PWID) are a key population for treatment with direct-acting antiviral medications (DAAs) to eliminate hepatitis C virus (HCV). We developed a Pharmacist, Physician, and Patient Navigator Collaborative Care Model (PPP-CCM) for delivery of HCV treatment; this study describes clinical outcomes related to HCV treatment (initial evaluation, treatment initiation, completion, and cure), as well as patient satisfaction. Methods: We conducted a single-arm prospective pilot study of adult PWID living with HCV. Participants completed baseline and six-month follow-up surveys, and treatment and outcomes were abstracted from electronic health records. Primary outcome was linkage to pharmacist for HCV evaluation; secondary outcomes included DAA initiation, completion, and cure, as well as patient-reported satisfaction. Results: Of the 40 PWID enrolled, mean age was 43.6 years, 12 (30 %) were female, 20 (50 %) were non-white, and 15 (38 %) were unhoused. Thirty-eight (95 %) were successfully linked to the pharmacist for initial evaluation. Of those, 21/38 (55 %) initiated DAAs, and 16/21 (76 %) completed treatment. Among those completing treatment who had viral load data to document whether they achieved "sustained virologic response", i.e. cure, 10/11 (91 %) were found to be cured. There was high satisfaction with 100 % responding "agree or strongly agree" that they had a positive experience with the pharmacist. Conclusion: Nearly all participants in this pilot were successfully linked to the pharmacist for evaluation, and more than half were started on DAAs; results provide preliminary evidence of feasibility of pharmacist-led models of HCV treatment for PWID. Clinicaltrialsgov Registration Number: NCT04698629. Competing Interests: The authors declare that all procedures were performed in compliance with relevant laws and institutional guidelines. Appropriate ethical safeguards, including privacy rights of human participants, and ethical approvals were obtained through the University of Washington's Institutional Review Board. (© 2024 The Authors. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu